Company news
Phio Pharmaceuticals Corp. news in 2024
Phio Pharmaceuticals Corp.'s news releases, calls and decks from 2024, newest first.
Phio Pharmaceuticals Announces Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 22, 2024
Phio Pharmaceuticals Announces Positive Safety Monitoring Committee (SMC) Recommendation to Continue to Third Dose Cohort in its Clinical Study of PH-762
December 18, 2024
Phio Pharmaceuticals Announces $1.15 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules
December 18, 2024
Phio Pharmaceuticals Announces Publication in Frontiers in Immunology
December 11, 2024
Phio Pharmaceuticals is a Finalist for the Technology Disruptor of the Year Award
December 9, 2024
Phio Pharmaceuticals Announces Completion of Enrollment in Second Cohort in Phase 1b Dose-Escalating Clinical Study
November 18, 2024
Phio Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update
November 13, 2024
Phio Pharmaceuticals Announces Upcoming Presentation at the 39th Annual Meeting of the Society for Immunotherapy of Cancer (SITC)
November 6, 2024
Phio Pharmaceuticals to Participate in the Renmark Financial Communications Virtual Non-deal Roadshow Series
October 17, 2024
Correction to Registration Link to Access Phio Pharmaceuticals' Presentation in the Renmark Financial Communications Virtual Non-Deal Roadshow Series
October 17, 2024
Phio Pharmaceuticals Presenting Data on Its INSTAYL Compound PH-894 at ASGCT's 2024 Advancing Gene and Cell Therapies for Cancer Conference
October 15, 2024
Phio Announces Data Showcasing INTASYL's Role in Helping Immune Cells Target and Kill Cancer Cells
October 6, 2024
Phio Pharmaceuticals Announces Upcoming Presentation at ASGCT's 2024 Advancing Gene + Cell Therapies for Cancer Conference
September 30, 2024
INTASYL Technology and Compounds to be Focus of Presentation at 20th Annual Meeting of Oligonucleotide Therapeutics Society
September 24, 2024
Phio Pharmaceuticals Announces Presentation at the 9th Annual CAR-TCR Summit in Boston, MA
September 15, 2024
Phio Pharmaceuticals to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 8, 2024
Phio Pharmaceuticals Reports Second Quarter 2024 Financial Results and Provides Business Update
August 13, 2024
Phio Pharmaceuticals Announces Exploratory Collaboration with a Luxury Skin Care Company for Phio's Patented INTASYL Compound
August 5, 2024
Phio Pharmaceuticals Announces New Chief Financial Officer
July 31, 2024
Phio Pharmaceuticals Announces Exercise of Warrants for $3.1 Million Gross Proceeds
July 11, 2024
Phio Pharmaceuticals Announces Addition of Clinical Trial Site for its Phase 1b study of PH-762
July 7, 2024
Phio Pharmaceuticals Terminates Share Purchase Agreement with Triton Funds
July 4, 2024
Phio Pharmaceuticals Announces Reverse Stock Split
July 1, 2024
Phio Pharmaceuticals Announces New Patent for INTASYL Compound That Targets Photo-aging
June 17, 2024
Phio Pharmaceuticals Announces Positive Recommendation from Safety Monitoring Committee (SMC) of Phase 1b Clinical Study of Phio's Lead Compound PH-762
May 27, 2024
Phio Pharmaceuticals Announces Presentation at the Annual Meeting of the American Society of Clinical Oncology (ASCO)
May 22, 2024
Phio Pharmaceuticals Secures New Investor
May 16, 2024
Phio Pharmaceuticals Presents This Week at the Society for Investigative Dermatology (SID)
May 15, 2024
Phio Pharmaceuticals Announces Completion of Dosing in First Patient Cohort in PH-762 Phase 1b Dose-Escalation Study
May 14, 2024
Phio Pharmaceuticals Reports Q1 2024 Results and Provides Business Update
May 8, 2024
Phio Pharmaceuticals Announces Upcoming Presentation at the Annual Meeting of the Society of Clinical Oncology (ASCO)
April 29, 2024
Intratumoral Injection of Phio’s PH-762 significantly inhibits tumor growth in murine tumor models and may generate memory-specific T cells
April 21, 2024
Phio Pharmaceuticals Announces Upcoming Presentations at the 81st Annual Meeting of the Society for Investigative Dermatology (SID)
April 15, 2024
Phio Pharmaceuticals Announces Upcoming Presentation at the 27th Annual Meeting of the American Society of Cell and Gene Therapy (ASCGT)
April 10, 2024
National Spotlight Features Phio’s Innovative RNAi Technology Platform
April 2, 2024
Phio Pharmaceuticals Reports 2023 Year End Financial Results and Provides Business Update
April 1, 2024
Phio Pharmaceuticals Presenting Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
March 20, 2024
Phio Pharmaceuticals Announces Addition of Clinical Trial Sites at Banner MD Anderson Cancer Center, The George Washington University, and Integrity Research
March 12, 2024
Phio Pharmaceuticals Announces Patent Granted by USPTO, Strengthening the Company’s Intellectual Property Position in Treating Aging Skin and Skin Disorders
March 5, 2024
Phio Pharmaceuticals Announces Data Showing INTASYL May Result in More Effective Cell Therapy for Hematological Malignancies
January 30, 2024